Exodus Point Capital Management, LP Eagle Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$17.74 - $31.87 $229,520 - $412,334	12,938 New	12,938 $252,000
Q4 2022 Feb 13, 2023	BUY	$24.98 - $39.77 $504,571 - $803,314	20,199 New	20,199 $590,000
Q3 2022 Nov 10, 2022	SELL	$26.42 - $47.12 $980,472 - $1.75 Million	-37,111 Closed	0 $0
Q2 2022 Aug 19, 2022	BUY	$41.26 - $51.35 $1.53 Million - $1.91 Million	37,111 New	37,111 $1.65 Million
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $610,180 - $736,653	-16,554 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $365,258 - $461,737	9,059 Added 120.87%	16,554 $691,000
Q4 2020 Feb 16, 2021	BUY	$41.72 - $51.34 $312,691 - $384,793	7,495 New	7,495 $349,000

5.33M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $15.4M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.